JZP-110
Phase 2Small molecule
Jazz PharmaceuticalsJZP-110 is one of 32 small molecule programs targeting Narcolepsy. It is currently in Phase 2.
1
Indications
7
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Narcolepsy
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Romazicon
CConrado Roberto Hoffmann Filho
Approved
Vivarin
HHikma Pharmaceuticals LLC
Approved
Provigil
NNuvo Research GmbH
Phase 3
Nuvigil
NNuvo Research GmbH
Phase 3
JZP-258
Jazz PharmaceuticalsApproved
Xyrem
Jazz PharmaceuticalsPhase 3
JZP258
Jazz PharmaceuticalsApproved
Vigil™
GGradalis, Inc.
Phase 3
TAK-861
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Excessive Sleepiness4 trials
Narcolepsy3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JZP-110. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company